Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

The European Medicines Agency issued a positive opinion in December for the approval of Omvoh for moderately to severely active Crohn's disease. More on Eli Lilly Eli Lilly Q4: Don't Miss Out On ...

Lilly (NYSE:LLY) has submitted marketing applications for Omvoh for Crohn's disease worldwide, including the European Union and Japan. The product is approved for the treatment of ulcerative ...

2 1. FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease. News release. Eli Lilly and Company.

A breakdown of Crohn’s disease, its symptoms, causes, and long-term impact on health. Explore the causes, symptoms, diagnosis ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Crohn's disease, also known as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Omvoh has been cleared on the strength of ... but recently scored a win in a phase 3 Crohn’s disease study and, if approved in that indication, analysts have suggested it could eventually ...

When symptoms flare up, it can be challenging for people with Crohn’s disease—a chronic inflammatory bowel disease–to ...

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through ...